AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a note issued to investors on Tuesday. They presently have a $10.00 target price on the specialty pharmaceutical company’s stock. HC Wainwright’s price objective suggests a potential upside of 81.82% from the company’s previous close.

Other analysts also recently issued reports about the stock. ValuEngine downgraded shares of AcelRx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Zacks Investment Research cut AcelRx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Roth Capital reaffirmed a “buy” rating and issued a $12.50 target price on shares of AcelRx Pharmaceuticals in a research report on Thursday, August 10th. Jefferies Group LLC reiterated a “buy” rating and set a $7.00 price target on shares of AcelRx Pharmaceuticals in a report on Friday, July 14th. Finally, Piper Jaffray Companies set a $3.00 price target on AcelRx Pharmaceuticals and gave the company a “hold” rating in a report on Tuesday, July 25th. One analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $7.93.

Shares of AcelRx Pharmaceuticals (ACRX) remained flat at $5.50 during midday trading on Tuesday. 3,881,359 shares of the company’s stock traded hands. The company has a 50-day moving average of $3.37 and a 200-day moving average of $2.87. The stock’s market capitalization is $249.59 million. AcelRx Pharmaceuticals has a 12-month low of $1.95 and a 12-month high of $5.75.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last issued its quarterly earnings results on Tuesday, August 1st. The specialty pharmaceutical company reported ($0.29) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.01). The company had revenue of $2.66 million for the quarter, compared to analyst estimates of $2.63 million. Equities research analysts expect that AcelRx Pharmaceuticals will post ($1.13) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/10/03/hc-wainwright-reiterates-buy-rating-for-acelrx-pharmaceuticals-inc-acrx.html.

In related news, CEO Vincent J. Angotti purchased 15,000 shares of the company’s stock in a transaction dated Thursday, August 24th. The shares were acquired at an average cost of $3.00 per share, with a total value of $45,000.00. Following the completion of the purchase, the chief executive officer now owns 15,000 shares of the company’s stock, valued at approximately $45,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Pamela P. Palmer purchased 10,000 shares of the company’s stock in a transaction dated Tuesday, August 22nd. The stock was bought at an average cost of $2.95 per share, for a total transaction of $29,500.00. The disclosure for this purchase can be found here. Insiders have acquired a total of 37,000 shares of company stock valued at $112,280 in the last three months. Company insiders own 28.10% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Teachers Advisors LLC boosted its position in AcelRx Pharmaceuticals by 14.6% during the fourth quarter. Teachers Advisors LLC now owns 66,715 shares of the specialty pharmaceutical company’s stock valued at $173,000 after purchasing an additional 8,475 shares during the last quarter. Bank of New York Mellon Corp grew its stake in AcelRx Pharmaceuticals by 6.6% in the first quarter. Bank of New York Mellon Corp now owns 112,682 shares of the specialty pharmaceutical company’s stock valued at $355,000 after purchasing an additional 6,942 shares in the last quarter. WealthTrust Axiom LLC grew its stake in AcelRx Pharmaceuticals by 50.0% in the second quarter. WealthTrust Axiom LLC now owns 210,000 shares of the specialty pharmaceutical company’s stock valued at $451,000 after purchasing an additional 70,000 shares in the last quarter. LMR Partners LLP purchased a new position in AcelRx Pharmaceuticals in the second quarter valued at about $319,000. Finally, Virtu KCG Holdings LLC grew its stake in AcelRx Pharmaceuticals by 600.9% in the second quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock valued at $255,000 after purchasing an additional 101,742 shares in the last quarter. 23.32% of the stock is owned by hedge funds and other institutional investors.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Analyst Recommendations for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.